PL362172A1 - Kompozycja farmaceutyczna o polepszonej wchłanialności - Google Patents
Kompozycja farmaceutyczna o polepszonej wchłanialnościInfo
- Publication number
- PL362172A1 PL362172A1 PL01362172A PL36217201A PL362172A1 PL 362172 A1 PL362172 A1 PL 362172A1 PL 01362172 A PL01362172 A PL 01362172A PL 36217201 A PL36217201 A PL 36217201A PL 362172 A1 PL362172 A1 PL 362172A1
- Authority
- PL
- Poland
- Prior art keywords
- medicinal compositions
- improved absorbability
- absorbability
- improved
- medicinal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000375608 | 2000-12-11 | ||
| PCT/JP2001/010827 WO2002048142A1 (fr) | 2000-12-11 | 2001-12-11 | Compositions medicamenteuses presentant une meilleure absorbabilite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL362172A1 true PL362172A1 (pl) | 2004-10-18 |
Family
ID=18844596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL01362172A PL362172A1 (pl) | 2000-12-11 | 2001-12-11 | Kompozycja farmaceutyczna o polepszonej wchłanialności |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040053972A1 (pl) |
| EP (1) | EP1350793A1 (pl) |
| KR (1) | KR20040025881A (pl) |
| CN (1) | CN1487936A (pl) |
| AU (1) | AU2002221115A1 (pl) |
| CA (1) | CA2431322A1 (pl) |
| HU (1) | HUP0400683A2 (pl) |
| NO (1) | NO20032614L (pl) |
| PL (1) | PL362172A1 (pl) |
| WO (1) | WO2002048142A1 (pl) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984653B2 (en) | 2001-10-05 | 2006-01-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| DK1667992T3 (da) * | 2003-09-19 | 2007-04-30 | Astrazeneca Ab | Quinazolinderivater |
| ES2379631T3 (es) * | 2003-10-08 | 2012-04-30 | Meiji Seika Pharma Co., Ltd. | Composición antibacteriana no cristalina que contiene cefditoren pivoxilo |
| US7259262B2 (en) * | 2003-10-24 | 2007-08-21 | Hoffmann-La Roche Inc. | Arylazole derivatives, their manufacture and use as pharmaceutical agents |
| JP4639745B2 (ja) * | 2004-01-19 | 2011-02-23 | 青葉化成株式会社 | 難固結性のタンパク質変性抑制剤粉末およびその使用方法 |
| WO2005074991A1 (ja) * | 2004-02-09 | 2005-08-18 | Kabushiki Kaisha Sangi | 抗腫瘍剤 |
| JP2008519047A (ja) * | 2004-11-05 | 2008-06-05 | セフアロン・インコーポレーテツド | 癌処置 |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| EP1849830B1 (en) * | 2005-01-28 | 2012-02-29 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| JP5097540B2 (ja) * | 2005-04-06 | 2012-12-12 | 株式会社サンギ | 腸管吸収用抗腫瘍剤 |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| NZ589883A (en) | 2008-05-13 | 2012-06-29 | Astrazeneca Ab | Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline |
| US7749300B2 (en) * | 2008-06-05 | 2010-07-06 | Xerox Corporation | Photochemical synthesis of bimetallic core-shell nanoparticles |
| CN104224703A (zh) * | 2008-09-25 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀的液体配制品 |
| UA109109C2 (uk) * | 2009-01-15 | 2015-07-27 | Сефалон, Інк. | Кристалічна форма вільної основи бендамустину (варіанти) та фармацевтична композиція для лікування раку (варіанти) |
| BR122020010643B1 (pt) * | 2011-10-14 | 2022-05-17 | Array Biopharma Inc | Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| AU4314196A (en) * | 1994-12-21 | 1996-07-10 | Yamanouchi Pharmaceutical Co., Ltd. | Solid composition with improved solubility and absorbability |
| CA2260999C (en) * | 1996-07-19 | 2006-07-11 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use in tyrosine kinase inhibition |
-
2001
- 2001-12-11 HU HU0400683A patent/HUP0400683A2/hu unknown
- 2001-12-11 AU AU2002221115A patent/AU2002221115A1/en not_active Abandoned
- 2001-12-11 CA CA002431322A patent/CA2431322A1/en not_active Abandoned
- 2001-12-11 US US10/433,720 patent/US20040053972A1/en not_active Abandoned
- 2001-12-11 WO PCT/JP2001/010827 patent/WO2002048142A1/ja not_active Application Discontinuation
- 2001-12-11 PL PL01362172A patent/PL362172A1/pl not_active Application Discontinuation
- 2001-12-11 CN CNA018224318A patent/CN1487936A/zh active Pending
- 2001-12-11 KR KR10-2003-7007802A patent/KR20040025881A/ko not_active Application Discontinuation
- 2001-12-11 EP EP01270221A patent/EP1350793A1/en not_active Withdrawn
-
2003
- 2003-06-10 NO NO20032614A patent/NO20032614L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002048142A1 (fr) | 2002-06-20 |
| AU2002221115A1 (en) | 2002-06-24 |
| CA2431322A1 (en) | 2002-06-20 |
| NO20032614L (no) | 2003-08-05 |
| CN1487936A (zh) | 2004-04-07 |
| EP1350793A1 (en) | 2003-10-08 |
| HUP0400683A2 (hu) | 2004-06-28 |
| US20040053972A1 (en) | 2004-03-18 |
| NO20032614D0 (no) | 2003-06-10 |
| KR20040025881A (ko) | 2004-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2358583B (en) | Pharmaceutical compositions | |
| IL152659A0 (en) | Pharmaceutical composition | |
| HK1075889A1 (en) | Pharmaceutical composition | |
| HUP0300582A3 (en) | Pharmaceutical compositions | |
| AU6219601A (en) | Pharmaceutical compositions | |
| HUP0204555A3 (en) | Pharmaceutical composition | |
| GB0009584D0 (en) | Pharmaceutical compositions | |
| AU8576801A (en) | Pharmaceutical compositions | |
| PL362172A1 (pl) | Kompozycja farmaceutyczna o polepszonej wchłanialności | |
| HUP0400553A3 (en) | Pharmaceutical compositions | |
| HK1057474A1 (en) | Medicinal composition | |
| IL154238A0 (en) | Pharmaceutical composition | |
| GB0008485D0 (en) | Pharmaceutical compositions | |
| GB0009613D0 (en) | Pharmaceutical compositions | |
| GB0009609D0 (en) | Therapeutic compositions | |
| GB0030857D0 (en) | Therapeutic compositions | |
| GB0005382D0 (en) | Pharmaceutical composition | |
| AU8254101A (en) | Medicinal compositions | |
| GB0002691D0 (en) | Pharmaceutical composition | |
| GB0101094D0 (en) | Pharmaceutical composition | |
| GB0019599D0 (en) | Pharmaceutical composition | |
| GB0027375D0 (en) | Pharmaceutical composition | |
| GB0026716D0 (en) | Pharmaceutical composition | |
| GB0006301D0 (en) | Pharmaceutical composition | |
| GB0016684D0 (en) | Pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |